Article Versions Notes

Sheffield BS, Eaton K, Emond B, Lafeuille M-H, Hilts A, Lefebvre P, Morrison L, Stevens AL, Ewara EM, Cheema P. Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices. Current Oncology. 2023; 30(2):2348-2365. https://doi.org/10.3390/curroncol30020180

Sheffield, Brandon S., Kiefer Eaton, Bruno Emond, Marie-Hélène Lafeuille, Annalise Hilts, Patrick Lefebvre, Laura Morrison, Andrea L. Stevens, Emmanuel M. Ewara, and Parneet Cheema. 2023. "Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices" Current Oncology 30, no. 2: 2348-2365. https://doi.org/10.3390/curroncol30020180

Sheffield, B. S., Eaton, K., Emond, B., Lafeuille, M.-H., Hilts, A., Lefebvre, P., Morrison, L., Stevens, A. L., Ewara, E. M., & Cheema, P. (2023). Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices. Current Oncology, 30(2), 2348-2365. https://doi.org/10.3390/curroncol30020180